Results from Clinical Trial Show Progenics’ PyL (18F-DCFPyL) PSMA PET/CT Imaging Agent Changes Management Plans for More Than 87% ...
NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that an analysis of an …